Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Ebiomedicine|June 7, 2021
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severityStine Sf Nielsen, Line K Vibholm, Ida Monrad, et al.Ebiomedicine|February 2, 2021
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responsesLine K Vibholm, Stine S F Nielsen, Marie H Pahus, et al.Nature Communications|October 30, 2022
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunityMiriam Rosás-Umbert, Jesper D Gunst, Marie H Pahus, et al.The Lancet. Microbe|May 11, 2022
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trialHenning Gruell, Jesper D Gunst, Yehuda Z Cohen, et al.Nature Medicine|October 17, 2022
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialJesper D Gunst, Marie H Pahus, Miriam Rosás-Umbert, et al.Nature Medicine|September 11, 2023
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trialJesper D Gunst, Jesper F Højen, Marie H Pahus, et al.Eclinicalmedicine|April 27, 2021
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trialJesper D Gunst, Nina B Staerke, Marie H Pahus, et al.Nature Immunology|March 3, 2026
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention controlKatie Fisher, Mauro A Garcia, Giacomo S Frattari, et al.Pageof 1